Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 193

1.

PI3K inhibitor GDC-0941 enhances apoptotic effects of BH-3 mimetic ABT-737 in AML cells in the hypoxic bone marrow microenvironment.

Jin L, Tabe Y, Kojima K, Shikami M, Benito J, Ruvolo V, Wang RY, McQueen T, Ciurea SO, Miida T, Andreeff M, Konopleva M.

J Mol Med (Berl). 2013 Dec;91(12):1383-97. doi: 10.1007/s00109-013-1076-3. Epub 2013 Aug 18.

2.

Inhibition of Mcl-1 with the pan-Bcl-2 family inhibitor (-)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia.

Pan R, Ruvolo VR, Wei J, Konopleva M, Reed JC, Pellecchia M, Andreeff M, Ruvolo PP.

Blood. 2015 Jul 16;126(3):363-72. doi: 10.1182/blood-2014-10-604975. Epub 2015 Jun 4.

3.

Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism.

Rahmani M, Aust MM, Attkisson E, Williams DC Jr, Ferreira-Gonzalez A, Grant S.

Cancer Res. 2013 Feb 15;73(4):1340-51. doi: 10.1158/0008-5472.CAN-12-1365. Epub 2012 Dec 12.

4.

Mechanisms of apoptosis induction by simultaneous inhibition of PI3K and FLT3-ITD in AML cells in the hypoxic bone marrow microenvironment.

Jin L, Tabe Y, Lu H, Borthakur G, Miida T, Kantarjian H, Andreeff M, Konopleva M.

Cancer Lett. 2013 Feb 1;329(1):45-58. doi: 10.1016/j.canlet.2012.09.020. Epub 2012 Oct 2.

5.

MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex.

Konopleva M, Milella M, Ruvolo P, Watts JC, Ricciardi MR, Korchin B, McQueen T, Bornmann W, Tsao T, Bergamo P, Mak DH, Chen W, McCubrey J, Tafuri A, Andreeff M.

Leukemia. 2012 Apr;26(4):778-87. doi: 10.1038/leu.2011.287. Epub 2011 Nov 8.

6.

Co-administration of the mTORC1/TORC2 inhibitor INK128 and the Bcl-2/Bcl-xL antagonist ABT-737 kills human myeloid leukemia cells through Mcl-1 down-regulation and AKT inactivation.

Rahmani M, Aust MM, Hawkins E, Parker RE, Ross M, Kmieciak M, Reshko LB, Rizzo KA, Dumur CI, Ferreira-Gonzalez A, Grant S.

Haematologica. 2015 Dec;100(12):1553-63. doi: 10.3324/haematol.2015.130351. Epub 2015 Oct 9.

7.

BMX acts downstream of PI3K to promote colorectal cancer cell survival and pathway inhibition sensitizes to the BH3 mimetic ABT-737.

Potter DS, Kelly P, Denneny O, Juvin V, Stephens LR, Dive C, Morrow CJ.

Neoplasia. 2014 Feb;16(2):147-57. doi: 10.1593/neo.131376.

8.

PI3K and Bcl-2 inhibition primes glioblastoma cells to apoptosis through downregulation of Mcl-1 and Phospho-BAD.

Pareja F, Macleod D, Shu C, Crary JF, Canoll PD, Ross AH, Siegelin MD.

Mol Cancer Res. 2014 Jul;12(7):987-1001. doi: 10.1158/1541-7786.MCR-13-0650. Epub 2014 Apr 22.

9.

Maritoclax induces apoptosis in acute myeloid leukemia cells with elevated Mcl-1 expression.

Doi K, Liu Q, Gowda K, Barth BM, Claxton D, Amin S, Loughran TP Jr, Wang HG.

Cancer Biol Ther. 2014 Aug;15(8):1077-86. doi: 10.4161/cbt.29186. Epub 2014 May 19.

10.

Phosphoinositide 3-kinase/AKT/mTORC1/2 signaling determines sensitivity of Burkitt's lymphoma cells to BH3 mimetics.

Spender LC, Inman GJ.

Mol Cancer Res. 2012 Mar;10(3):347-59. doi: 10.1158/1541-7786.MCR-11-0394. Epub 2012 Jan 12.

11.

Combination of galectin inhibitor GCS-100 and BH3 mimetics eliminates both p53 wild type and p53 null AML cells.

Ruvolo PP, Ruvolo VR, Benton CB, AlRawi A, Burks JK, Schober W, Rolke J, Tidmarsh G, Hail N Jr, Davis RE, Andreeff M.

Biochim Biophys Acta. 2016 Apr;1863(4):562-71. doi: 10.1016/j.bbamcr.2015.12.008. Epub 2015 Dec 17.

12.

Pan-mammalian target of rapamycin (mTOR) inhibitor AZD8055 primes rhabdomyosarcoma cells for ABT-737-induced apoptosis by down-regulating Mcl-1 protein.

Preuss E, Hugle M, Reimann R, Schlecht M, Fulda S.

J Biol Chem. 2013 Dec 6;288(49):35287-96. doi: 10.1074/jbc.M113.495986. Epub 2013 Oct 16.

13.

Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia.

Iacovelli S, Ricciardi MR, Allegretti M, Mirabilii S, Licchetta R, Bergamo P, Rinaldo C, Zeuner A, Foà R, Milella M, McCubrey JA, Martelli AM, Tafuri A.

Oncotarget. 2015 Oct 13;6(31):32089-103. doi: 10.18632/oncotarget.5156.

14.

ABT-737 synergizes with bortezomib to induce apoptosis, mediated by Bid cleavage, Bax activation, and mitochondrial dysfunction in an Akt-dependent context in malignant human glioma cell lines.

Premkumar DR, Jane EP, DiDomenico JD, Vukmer NA, Agostino NR, Pollack IF.

J Pharmacol Exp Ther. 2012 Jun;341(3):859-72. doi: 10.1124/jpet.112.191536. Epub 2012 Mar 5.

15.

Proteasomal degradation of Mcl-1 by maritoclax induces apoptosis and enhances the efficacy of ABT-737 in melanoma cells.

Pandey MK, Gowda K, Doi K, Sharma AK, Wang HG, Amin S.

PLoS One. 2013 Nov 4;8(11):e78570. doi: 10.1371/journal.pone.0078570. eCollection 2013.

16.
17.

Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis.

Simonin K, N'Diaye M, Lheureux S, Loussouarn C, Dutoit S, Briand M, Giffard F, Brotin E, Blanc-Fournier C, Poulain L.

Apoptosis. 2013 Apr;18(4):492-508. doi: 10.1007/s10495-012-0799-x.

PMID:
23344663
18.

ABT-737 resistance in B-cells isolated from chronic lymphocytic leukemia patients and leukemia cell lines is overcome by the pleiotropic kinase inhibitor quercetin through Mcl-1 down-regulation.

Russo M, Spagnuolo C, Volpe S, Tedesco I, Bilotto S, Russo GL.

Biochem Pharmacol. 2013 Apr 1;85(7):927-36. doi: 10.1016/j.bcp.2013.01.011. Epub 2013 Jan 24.

PMID:
23353698
19.

Antileukemic Activity of 2-Deoxy-d-Glucose through Inhibition of N-Linked Glycosylation in Acute Myeloid Leukemia with FLT3-ITD or c-KIT Mutations.

Larrue C, Saland E, Vergez F, Serhan N, Delabesse E, Mansat-De Mas V, Hospital MA, Tamburini J, Manenti S, Sarry JE, Récher C.

Mol Cancer Ther. 2015 Oct;14(10):2364-73. doi: 10.1158/1535-7163.MCT-15-0163. Epub 2015 Jul 23.

20.

Actinomycin D synergistically enhances the efficacy of the BH3 mimetic ABT-737 by downregulating Mcl-1 expression.

Olberding KE, Wang X, Zhu Y, Pan J, Rai SN, Li C.

Cancer Biol Ther. 2010 Nov 1;10(9):918-29. doi: 10.4161/cbt.10.9.13274. Epub 2010 Nov 1.

Supplemental Content

Support Center